Merit Financial Group LLC Has $1.05 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Merit Financial Group LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 302.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,859 shares of the biopharmaceutical company’s stock after purchasing an additional 1,397 shares during the period. Merit Financial Group LLC’s holdings in Regeneron Pharmaceuticals were worth $1,045,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $31,000. Traub Capital Management LLC bought a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $38,000. Berbice Capital Management LLC raised its position in Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 60 shares in the last quarter. Westside Investment Management Inc. lifted its stake in Regeneron Pharmaceuticals by 62.0% during the second quarter. Westside Investment Management Inc. now owns 81 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 31 shares during the last quarter. Finally, Ameritas Advisory Services LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $45,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.7%

REGN opened at $776.54 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $792.77. The company’s 50 day moving average price is $729.10 and its two-hundred day moving average price is $623.54. The firm has a market capitalization of $81.61 billion, a price-to-earnings ratio of 18.60, a PEG ratio of 2.28 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same quarter in the previous year, the business earned $12.46 earnings per share. Regeneron Pharmaceuticals’s revenue was up .9% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Canaccord Genuity Group boosted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Citigroup upped their price objective on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, HSBC assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a “buy” rating and a $255.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $779.45.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.